

## MSK Levels of Evidence



Level 1

**FDA-recognized** biomarker predictive of response to an **FDA-approved** drug **in this indication** 

Level 2A

**Standard care** biomarker predictive of response to an **FDA-approved** drug **in this indication**\*

Level 2B

**Standard care** biomarker predictive of response to an **FDA-approved** drug **in another indication**, but not standard care for this indication

Level 3A

**Compelling clinical evidence** supports the biomarker as being predictive of response to a drug **in this indication**, but neither biomarker nor drug are standard care

Level 3B

**Compelling clinical evidence** supports the biomarker as being predictive of response to a drug in another indication, but neither biomarker nor drug are standard care

Level 4

**Compelling biological evidence** supports the biomarker as being predictive of response to a drug, but neither biomarker nor drug are standard care

Standard Therapeutic Implications

\*Includes biomarkers
that are recommended
as standard care
by the NCCN or
other expert panels
but not necessarily
FDA-recognized
for a particular
indication

Investigational
Therapeutic
Implications
possibly directed
to clinical trials

Hypothetical Therapeutic Implications

based on preliminary, nonclinical data

Level R1 **Standard care** biomarker predictive of **resistance** to an **FDA-approved** drug **in this indication** 

Standard Therapeutic Implications